Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond

Lab on a Chip ◽  
2018 ◽  
Author(s):  
Ramanathan Vaidyanathan ◽  
Ren Hao Soon ◽  
Pan Zhang ◽  
Kuan Jiang ◽  
Chwee Teck Lim
Keyword(s):  
Real Time ◽  
Cancer Diagnosis ◽  
Liquid Biopsy ◽  
Patient Monitoring ◽  
Circulating Biomarkers ◽  
Less Invasive

Technological advancements in research on circulating biomarkers from patient derived blood have enabled a less invasive means of diagnosing non-hematologic cancers. Considered a more practical way of real-time patient monitoring...

Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics

The Analyst ◽  
2016 ◽  
Vol 141 (2) ◽  
pp. 382-392 ◽  
Author(s):  
Kyung-A Hyun ◽  
Junmoo Kim ◽  
Hogyeong Gwak ◽  
Hyo-Il Jung
Keyword(s):  
Cancer Screening ◽  
Disease Progression ◽  
Real Time ◽  
Liquid Biopsy ◽  
Circulating Biomarkers ◽  
Real Time Monitoring ◽  
Tissue Biopsy

A liquid biopsy is more practical for real-time monitoring of disease progression than tissue biopsy.

scholarly journals Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1794
Author(s):  
Alice Indini ◽  
Erika Rijavec ◽  
Francesco Grossi
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Liquid Biopsy ◽  
Cytotoxic T Lymphocyte ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Circulating Biomarkers ◽  
Small Cell Lung ◽  
Nsclc Patients

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death (PD)-1 protein and its ligand, PD-L1, and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, have revolutionized the management of patients with advanced non-small cell lung cancer (NSCLC). Unfortunately, only a small portion of NSCLC patients respond to these agents. Furthermore, although immunotherapy is usually well tolerated, some patients experience severe immune-related adverse events (irAEs). Liquid biopsy is a non-invasive diagnostic procedure involving the isolation of circulating biomarkers, such as circulating tumor cells (CTC), cell-free DNA (cfDNA), and microRNAs (miRNAs). Thanks to recent advances in technologies, such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), liquid biopsy has become a useful tool to provide baseline information on the tumor, and to monitor response to treatments. This review highlights the potential role of liquid biomarkers in the selection of NSCLC patients who could respond to immunotherapy, and in the identification of patients who are most likely to experience irAEs, in order to guide improvements in care.

scholarly journals 191TiP Accelerating lung cancer diagnosis through liquid biopsy

2021 ◽  
Vol 16 (4) ◽  
pp. S801-S802
Author(s):  
M. García Pardo de Santayana ◽  
K. Czarnecka ◽  
T. Waddell ◽  
T. Stockley ◽  
J. Law ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Liquid Biopsy ◽  
Lung Cancer Diagnosis

scholarly journals Isolation of Circulating Biomarkers for Liquid Biopsy using Immunoaffinity‐Based Stimuli‐Responsive Hybrid Hydrogel Beads

2021 ◽  
Author(s):  
Yoon-Tae Kang ◽  
Young Jun Kim ◽  
Brittany Rupp ◽  
Emma Purcell ◽  
Thomas Hadlock ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Stimuli Responsive ◽  
Circulating Biomarkers ◽  
Hybrid Hydrogel ◽  
Hydrogel Beads
Sign in / Sign up

Export Citation Format

Share Document